Navigation Links
Boston Scientific Announces Results for First Quarter Ended March 31, 2008
Date:4/21/2008

NATICK, Mass., April 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2008, as well as guidance for net sales and earnings per share (EPS) for the second quarter of 2008.

First quarter highlights:

-- Achieved net sales of $2.046 billion and adjusted EPS of $0.24

-- Improved earnings through ongoing, stringent expense management

-- Maintained leading position in the worldwide drug-eluting stent (DES)

market

-- Received approval for six cardiac rhythm management (CRM) products

-- Grew Neuromodulation sales 40 percent

-- Increased Endosurgery sales nine percent

-- Completed the sale of five non-strategic businesses

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Our earnings benefited from our ongoing expense management and were also helped by favorable tax items. Despite the arrival of a third DES competitor in the United States, we held our leadership positions in both the U.S. and worldwide markets. Our six CRM product approvals were exciting news, and they will contribute to our future growth in that market. The performance of our Neuromodulation group was impressive, and our Endosurgery group turned in another solid quarter. Our progress furthered our goals of restoring profitable sales growth, increasing shareholder value and strengthening Boston Scientific for the future."

Net sales for the first quarter of 2008 were $2.046 billion, including sales from divested businesses of $32 million, as compared to $2.086 bi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin Competitive ... been accepted by AOAC International as Official First Action method. The AOAC Official ... R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac toxic ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... N.Y., March 20 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... pre-clinical program in Hepatitis C focused on the ... Inc. Presidio,is a private biotechnology company focused on ... backed by some of the,most prominent investors in ...
... Corporation, a leading,provider of fully integrated imaging ... of its real-time patient and resource,scheduler software, ... staff, rooms with drag and drop ease,delivering ... ROI., A free CardioSchedule Information Kit ...
... March 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... announced that AMT,s Supervisory Board has decided to ... Board at its Annual,General Meeting of shareholders on ... of TomTom (Euronext Amsterdam: TOM2), and has been,instrumental ...
Cached Biology Technology:XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 2XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 3XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 4LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... A major initiative to create alternative nesting sites for the ... help protect juvenile salmon and steelhead in the Columbia River ... nesting site at Crump Lake in southern Oregon, which was just ... more than 135 nesting pairs of Caspian terns, as well as ...
... called for Europe to invest more funds into the study ... role in the function of human cells and which are ... to Alzheimer,s. Common lipids such as cholesterol are known ... cells and tissues, but human cells contain thousands of different ...
... Belfast is appealing for help from the public in looking ... Activities such as aquaculture, shipping and recreational boating have led ... Now Queen,s is attempting to find out exactly where and how ... this it is asking for help from the public to record ...
Cached Biology News:Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6Europe-wide investment in lipid research will help tackle disease, says new report 2Queen's marine biologist investigates aliens beneath the waves 2
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
Biology Products: